CytomX Therapeutics, Inc. (CTMX)

Latest Insider Confidence Score

2026Q1

49.7
Bearish

Company insider confidence (by quarter)

2015Q4 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Bvf Partners L P/Il — 5,468,599 Feb 18, 2021
Biotechnology Value Fund L P — 5,468,599 Feb 18, 2021
Bvf I Gp Llc — 5,468,599 Feb 18, 2021
Biotechnology Value Fund II Lp — 5,468,599 Feb 18, 2021
Bvf II Gp Llc — 5,468,599 Feb 18, 2021

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Feb 2, 2026 Feb 4, 2026 Lester Rachael Chief Business Officer Neutral 90.0 +20,000 100.00% ✗ -
Feb 2, 2026 Feb 4, 2026 Chu Yu-Waye Chief Medical Officer Neutral 90.0 +75,000 55.26% ✗ -
Feb 2, 2026 Feb 4, 2026 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 90.0 +60,000 22.04% ✗ -
Feb 2, 2026 Feb 4, 2026 Ogden Christopher CFO Neutral 90.0 +90,000 39.78% ✗ -
Feb 2, 2026 Feb 4, 2026 McCarthy Sean A. CEO Neutral 90.0 +210,000 19.43% ✗ -
Nov 6, 2025 Nov 10, 2025 McCarthy Sean A. CEO Sell 26.3 -101,793 -8.61% ✓ $461.9K
Oct 20, 2025 Oct 29, 2025 Lester Rachael Chief Business Officer Neutral 52.5 - 0.00% ✗ -
Oct 29, 2025 Lester Rachael Chief Business Officer Neutral 52.5 - 0.00% ✗ -
Sep 26, 2025 Sep 30, 2025 McCarthy Sean A. CEO Neutral 52.5 - 0.00% ✗ -
Sep 26, 2025 Sep 30, 2025 Chu Yu-Waye Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Sep 26, 2025 Sep 30, 2025 Ogden Christopher CFO Neutral 52.5 - 0.00% ✗ -
Sep 26, 2025 Sep 30, 2025 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Jun 13, 2025 Jun 17, 2025 Ogden Christopher CFO Sell 46.3 -12,255 -2.80% ✗ $33.4K
Jun 13, 2025 Jun 17, 2025 BELVIN MARCIA SVP, Chief Scientific Officer Sell 46.3 -13,884 -4.85% ✗ $37.3K
Jun 13, 2025 Jun 17, 2025 McCarthy Sean A. CEO Sell 42.5 -55,511 -4.48% ✗ $149.3K
Jun 11, 2025 Jun 13, 2025 Su Zhen Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Young Matthew P. Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Mohindru Mani Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Meyers James R Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Jones Elaine V Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Gilbert Halley E Director Neutral 52.5 - 0.00% ✗ -
Jun 11, 2025 Jun 13, 2025 Ashworth Alan Director Neutral 52.5 - 0.00% ✗ -
Mar 18, 2025 Mar 20, 2025 McCarthy Sean A. CEO Sell 46.3 -37,656 -3.34% ✗ $22.6K
Mar 18, 2025 Mar 20, 2025 Ogden Christopher CFO Sell 47.5 -8,551 -4.08% ✗ $5.1K
Mar 18, 2025 Mar 20, 2025 Chu Yu-Waye Chief Medical Officer Sell 47.5 -4,025 -2.88% ✗ $2.4K
Mar 18, 2025 Mar 20, 2025 ROWLAND LLOYD A General Counsel Sell 47.5 -10,203 -7.80% ✗ $6.1K
Mar 18, 2025 Mar 20, 2025 BELVIN MARCIA SVP, Chief Scientific Officer Sell 46.3 -19,512 -7.28% ✗ $11.7K
Feb 4, 2025 Feb 10, 2025 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 90.0 +92,500 52.66% ✗ -
Feb 4, 2025 Feb 6, 2025 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 90.0 +87,500 49.82% ✗ -
Feb 4, 2025 Feb 6, 2025 Chu Yu-Waye Chief Medical Officer Neutral 90.0 +113,500 432.38% ✗ -
Feb 4, 2025 Feb 6, 2025 Ogden Christopher CFO Neutral 90.0 +101,500 93.91% ✗ -
Feb 4, 2025 Feb 6, 2025 McCarthy Sean A. CEO Neutral 90.0 +375,000 49.93% ✗ -
Aug 20, 2024 Aug 22, 2024 Landau Jeffrey B Chief Business Officer Sell 47.5 -4,181 -3.19% ✗ $5.1K
Aug 20, 2024 Aug 22, 2024 BELVIN MARCIA SVP, Chief Scientific Officer Sell 47.5 -4,181 -2.32% ✗ $5.1K
Aug 20, 2024 Aug 22, 2024 ROWLAND LLOYD A General Counsel Sell 47.5 -4,181 -3.10% ✗ $5.1K
Aug 20, 2024 Aug 22, 2024 Ogden Christopher CFO Sell 47.5 -1,984 -1.80% ✗ $2.4K
Aug 20, 2024 Aug 22, 2024 McCarthy Sean A. CEO Sell 46.3 -13,898 -1.82% ✗ $17.1K
Jun 12, 2024 Jun 14, 2024 Ogden Christopher CFO Neutral 90.0 +17,500 20.42% ✗ -
May 15, 2024 May 17, 2024 Young Matthew P. Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Su Zhen Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Mohindru Mani Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Meyers James R Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Jones Elaine V Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Gilbert Halley E Director Neutral 52.5 - 0.00% ✗ -
May 15, 2024 May 17, 2024 Ashworth Alan Director Neutral 52.5 - 0.00% ✗ -
Mar 26, 2024 Mar 28, 2024 McCarthy Sean A. CEO Neutral 52.5 - 0.00% ✗ -
Mar 20, 2024 Mar 22, 2024 Su Zhen Director Neutral 52.5 - 0.00% ✗ -
Mar 22, 2024 Su Zhen Director Neutral 52.5 - 0.00% ✗ -
Mar 19, 2024 Mar 21, 2024 ROWLAND LLOYD A General Counsel Sell 46.3 -5,268 -4.28% ✗ $11K
Mar 19, 2024 Mar 21, 2024 McCarthy Sean A. CEO Sell 46.3 -20,223 -3.17% ✗ $42.2K
Mar 19, 2024 Mar 21, 2024 Ogden Christopher SVP, Finance and Accounting Sell 47.5 -2,971 -3.35% ✗ $6.2K
Mar 19, 2024 Mar 21, 2024 BELVIN MARCIA SVP, Chief Scientific Officer Sell 46.3 -12,795 -7.05% ✗ $26.7K
Mar 19, 2024 Mar 21, 2024 Landau Jeffrey B Chief Business Officer Sell 46.3 -6,562 -5.28% ✗ $13.7K
Jan 18, 2024 Jan 19, 2024 McCarthy Sean A. CEO Neutral 90.0 +90,000 16.43% ✗ -
Jan 18, 2024 Jan 19, 2024 ROWLAND LLOYD A General Counsel Neutral 90.0 +25,000 25.51% ✗ -
Jan 18, 2024 Jan 19, 2024 Ogden Christopher SVP, Finance and Accounting Neutral 90.0 +40,000 82.21% ✗ -
Jan 18, 2024 Jan 19, 2024 Landau Jeffrey B Chief Business Officer Neutral 90.0 +30,000 31.81% ✗ -
Jan 18, 2024 Jan 19, 2024 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 90.0 +26,250 16.92% ✗ -
Jan 18, 2024 Jan 19, 2024 Chu Yu-Waye Chief Medical Officer Neutral 90.0 +26,250 100.00% ✗ -
Dec 20, 2023 Dec 22, 2023 McCarthy Sean A. CEO Sell 46.3 -13,551 -2.41% ✗ $18.7K
Dec 20, 2023 Dec 22, 2023 BELVIN MARCIA SVP, Chief Scientific Officer Sell 47.5 -4,077 -2.56% ✗ $5.6K
Dec 20, 2023 Dec 22, 2023 Landau Jeffrey B Chief Business Officer Sell 47.5 -4,077 -4.14% ✗ $5.6K
Dec 20, 2023 Dec 22, 2023 ROWLAND LLOYD A General Counsel Sell 47.5 -4,077 -3.99% ✗ $5.6K
Dec 20, 2023 Dec 22, 2023 Ogden Christopher SVP, Finance and Accounting Sell 47.5 -1,990 -3.93% ✗ $2.7K
Dec 17, 2023 Dec 19, 2023 Ogden Christopher SVP, Finance and Accounting Neutral 52.5 - 0.00% ✗ -
Dec 17, 2023 Dec 19, 2023 McCarthy Sean A. CEO Neutral 52.5 - 0.00% ✗ -
Dec 17, 2023 Dec 19, 2023 Landau Jeffrey B Chief Business Officer Neutral 52.5 - 0.00% ✗ -
Dec 17, 2023 Dec 19, 2023 ROWLAND LLOYD A General Counsel Neutral 52.5 - 0.00% ✗ -
Dec 17, 2023 Dec 19, 2023 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Sep 20, 2023 Sep 22, 2023 BELVIN MARCIA SVP, Chief Scientific Officer Sell 85.0 +7,131 5.06% ✗ $5.4K
Sep 20, 2023 Sep 22, 2023 Landau Jeffrey B Chief Business Officer Sell 85.0 +7,131 9.27% ✗ $5.4K
Sep 20, 2023 Sep 22, 2023 McCarthy Sean A. CEO Sell 86.3 +25,399 5.09% ✗ $19K
Sep 20, 2023 Sep 22, 2023 ROWLAND LLOYD A General Counsel Sell 90.0 +9,514 13.38% ✗ $7.1K
Jul 19, 2023 Jul 20, 2023 Chu Yu-Waye Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jul 20, 2023 Chu Yu-Waye Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Meyers James R Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Mohindru Mani Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Young Matthew P. Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Ashworth Alan Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Gilbert Halley E Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 Jones Elaine V Director Neutral 52.5 - 0.00% ✗ -
May 19, 2023 May 23, 2023 McCarthy Sean A. CEO Neutral 52.5 - 0.00% ✗ -
Mar 29, 2023 Mar 31, 2023 Jones Elaine V Director Buy 90.0 +5,000 3521.13% ✗ $7.8K
Mar 22, 2023 Mar 29, 2023 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 90.0 +60,000 74.24% ✗ -
Mar 29, 2023 BELVIN MARCIA SVP, Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Mar 16, 2023 Mar 20, 2023 Ogden Christopher SVP, Finance and Accounting Sell 47.5 -516 -1.35% ✗ $1K
Mar 16, 2023 Mar 20, 2023 McCarthy Sean A. CEO Sell 46.3 -7,121 -1.46% ✗ $13.4K
Mar 16, 2023 Mar 20, 2023 Campoy Carlos CFO Sell 47.5 -1,748 -4.37% ✗ $3.5K
Mar 16, 2023 Mar 20, 2023 ROWLAND LLOYD A General Counsel Sell 47.5 -2,037 -2.79% ✗ $4K
Mar 16, 2023 Mar 20, 2023 Landau Jeffrey B CFO Sell 47.5 -1,477 -1.88% ✗ $2.9K
Mar 16, 2023 Mar 20, 2023 Peterson Amy C. EVP, Chief Development Officer Sell 47.5 -4,257 -6.79% ✗ $8.4K
Feb 2, 2023 Feb 6, 2023 McCarthy Sean A. CEO Neutral 90.0 +105,000 27.34% ✗ -
Feb 2, 2023 Feb 6, 2023 Landau Jeffrey B Chief Business Officer Neutral 90.0 +40,000 104.15% ✗ -
Feb 2, 2023 Feb 6, 2023 ROWLAND LLOYD A General Counsel Neutral 90.0 +25,000 51.94% ✗ -
Feb 2, 2023 Feb 6, 2023 Ogden Christopher SVP, Finance and Accounting Neutral 90.0 +25,000 188.14% ✗ -
Aug 10, 2022 Aug 12, 2022 McCarthy Sean A. CEO Neutral 52.5 - 0.00% ✗ -
Aug 10, 2022 Aug 12, 2022 Landau Jeffrey B Chief Business Officer Neutral 52.5 - 0.00% ✗ -
Aug 10, 2022 Aug 12, 2022 Ogden Christopher SVP, Finance and Accounting Neutral 52.5 - 0.00% ✗ -
Aug 10, 2022 Aug 12, 2022 ROWLAND LLOYD A General Counsel Neutral 52.5 - 0.00% ✗ -
Jul 19, 2022 Jul 21, 2022 Peterson Amy C. EVP, Chief Development Officer Sell 91.3 +12,537 25.00% ✗ $10.6K